Silverback Therapeutics, Inc. SBTX

SBTX Quotes by TradingView
Institutional shares held 62.7 Million
872K calls
589K puts
Total value of holdings $0
$0 calls
$0 puts
Market Cap N/A
Institutional ownership 176.78%
# of Institutions 163

Quarterly Institutional Activity in SBTX

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding SBTX

View all
View all

Latest Institutional Activity in SBTX

Top Purchases

Q3 2024
Woodline Partners LP Shares Held: 986K ($0)
705K Shares purchased
250.71% Added
Q3 2024
First Turn Management, LLC Shares Held: 593K ($0)
593K Shares purchased
New Holding
Q3 2024
Duquesne Family Office LLC Shares Held: 537K ($0)
537K Shares purchased
New Holding
Q3 2024
Morgan Stanley Shares Held: 639K ($0)
505K Shares purchased
377.27% Added
Q3 2024
Millennium Management LLC Shares Held: 487K ($0)
487K Shares purchased
New Holding
View All Buyers

Top Sells

Q3 2024
K2 Principal Fund, L.P. Shares Held: 120K ($0)
2.34M Shares sold
95.13% Reduced
Q3 2024
Orbimed Advisors LLC Shares Held: 8.29M ($0)
952K Shares sold
10.31% Reduced
Q3 2024
Nextech Invest Ag Shares Held: 1.11M ($0)
797K Shares sold
41.73% Reduced
Q3 2024
Invesco Ltd. Shares Held: 126K ($0)
295K Shares sold
70.13% Reduced
Q3 2024
Goldman Sachs Group Inc Shares Held: 276K ($0)
165K Shares sold
37.41% Reduced
View All Sellers

About SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

SBTX Chart by TradingView
SBTX Fundamental Data by TradingView

Insider Transactions at SBTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Nov 12 2024
Richard E Lowenthal PRESIDENT AND CEO
SELL
Open market or private sale
Indirect
100,000 -1.9%
$1,700,000 $17.2 P/Share
Nov 12 2024
Sarina Tanimoto CHIEF MEDICAL OFFICER
SELL
Open market or private sale
Indirect
100,000 -1.9%
$1,700,000 $17.2 P/Share
Nov 12 2024
James E Flynn > 10% Shareholder
SELL
Open market or private sale
Indirect
34,814 -0.17%
$591,838 $17.47 P/Share
Nov 11 2024
James E Flynn > 10% Shareholder
SELL
Open market or private sale
Indirect
528,456 -2.4%
$8,983,752 $17.8 P/Share
Oct 16 2024
Kathleen D. Scott Chief Financial Officer
SELL
Open market or private sale
Direct
12,500 -71.64%
$200,000 $16.0 P/Share
Oct 16 2024
Kathleen D. Scott Chief Financial Officer
BUY
Exercise of conversion of derivative security
Direct
12,500 +41.74%
$12,500 $1.5 P/Share
Oct 15 2024
Richard E Lowenthal PRESIDENT AND CEO
SELL
Open market or private sale
Indirect
100,000 -2.39%
$1,400,000 $15.0 P/Share
Oct 15 2024
Sarina Tanimoto CHIEF MEDICAL OFFICER
SELL
Open market or private sale
Indirect
100,000 -2.39%
$1,400,000 $15.0 P/Share
Oct 08 2024
Richard E Lowenthal PRESIDENT AND CEO
SELL
Open market or private sale
Indirect
100,000 -3.58%
$1,300,000 $13.83 P/Share
Oct 08 2024
Sarina Tanimoto CHIEF MEDICAL OFFICER
SELL
Open market or private sale
Indirect
100,000 -3.58%
$1,300,000 $13.83 P/Share
Sep 18 2024
Eric Karas Chief Commercial Officer
BUY
Exercise of conversion of derivative security
Direct
10,000 +38.92%
$10,000 $1.5 P/Share
Sep 17 2024
Sarina Tanimoto CHIEF MEDICAL OFFICER
SELL
Open market or private sale
Indirect
100,000 -3.4%
$1,200,000 $12.93 P/Share
Sep 17 2024
Richard E Lowenthal PRESIDENT AND CEO
SELL
Open market or private sale
Indirect
100,000 -3.4%
$1,200,000 $12.93 P/Share
Sep 10 2024
Sarina Tanimoto CHIEF MEDICAL OFFICER
SELL
Open market or private sale
Indirect
100,000 -3.4%
$1,100,000 $11.5 P/Share
Sep 10 2024
Richard E Lowenthal PRESIDENT AND CEO
SELL
Open market or private sale
Indirect
100,000 -3.4%
$1,100,000 $11.5 P/Share
Aug 26 2024
Peter A. Thompson Director
SELL
Open market or private sale
Indirect
83,695 -100.0%
$1,088,035 $13.0 P/Share
Aug 26 2024
Orbimed Advisors LLC Director
SELL
Open market or private sale
Indirect
83,695 -100.0%
$1,088,035 $13.0 P/Share
Aug 23 2024
Peter A. Thompson Director
SELL
Open market or private sale
Indirect
69,500 -45.37%
$903,500 $13.03 P/Share
Aug 23 2024
Orbimed Advisors LLC Director
SELL
Open market or private sale
Indirect
69,500 -45.37%
$903,500 $13.03 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
3.5M Shares
From 7 Insiders
Open market or private purchase 1.4M shares
Exercise of conversion of derivative security 764K shares
Bona fide gift 1.33M shares
Sell / Disposition
12.7M Shares
From 10 Insiders
Open market or private sale 6M shares
Bona fide gift 4M shares
Other acquisition or disposition 2.67M shares

Track Institutional and Insider Activities on SBTX

Follow Silverback Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SBTX shares.

Notify only if

Insider Trading

Get notified when an Silverback Therapeutics, Inc. insider buys or sells SBTX shares.

Notify only if

News

Receive news related to Silverback Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SBTX